Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about BHC, unsubscribe in one click. Privacy
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Perfluorohexyloctane FDA approved May 2023 · Miebo |
Dry Eye | Phase 4 · NCT06346340 | Completed |
| Rifaximin FDA approved May 2004 · Xifaxan |
Diarrhea | Phase 4 · NCT07285785 | Recruiting |
| Bupropion Hydrobromide FDA approved Apr 2008 · Aplenzin |
Major Depressive Disorder | Phase 4 · NCT02129751 | Not yet recruiting |
| Plecanatide FDA approved Jan 2017 · Trulance |
Irritable Bowel Syndrome Characterized by Constipation | Phase 3 · NCT02387359 | Completed |
| Lifitegrast FDA approved Jul 2016 · Xiidra |
Dry Eye Disease | Phase 2 · NCT07128628 | Completed |
| Brodalumab FDA approved Feb 2017 · Siliq |
Breast Cancer | Phase 1 · NCT06673329 | Recruiting |
| (Xiidra®) Lifitegrast Ophthalmic Solution 5.0% | Ocular Surface Disease | Phase 4 · NCT07490535 | Not yet recruiting |
| Miebo four times per day | Dry Eye Syndrome (DES) | Phase 4 · NCT07650708 | Recruiting |
| High dose budesonide rectal foam | Ulcerative Colitis | Phase 4 · NCT05976802 | Not yet recruiting |
| IDP-122 Lotion | Psoriasis | Phase 4 · NCT03987763 | Active not recruiting |
| IDP-118 Lotion | Psoriasis | Phase 4 · NCT03988439 | Completed |
| Determine the ability of the TearScience™… | Dry Eye | Phase 4 · NCT07722624 | Active not recruiting |
| Determine the ability of the iTrace™, BOSA™… | Dry Eye | Phase 4 · NCT07790211 | Recruiting |
| CABTREO is a fixed-combination product of… | Acne Vulgaris | Phase 4 · NCT07524946 | Recruiting |
| BTOS-HA | Ocular Redness | Phase 3 · NCT06803654 | Completed |
| IDP-120 Gel | Acne Vulgaris | Phase 3 · NCT03664752 | Completed |
Also used in these trials (approved or third-party drugs, not BHC's own candidates): Clindamycin Phosphate.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
BHC holds $2.5B in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when BHC files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| John Paulson Director |
Insider | 73,696,831 | 19.69% | 2026-09-30 |
| PAULSON & CO. INC. 10% owner |
Insider | 73,255,869 | 19.57% | 2025-11-25 |
| Alex Meruelo | 5%+ holder (13D) | 36,761,788 | 9.82% | 2025-03-31 |
| Icahn Capital LP | 5%+ holder (13D) | 34,721,118 | 9.28% | 2025-05-20 |
| Goldentree Asset Management LP | Institution (13F) | 34,665,731 | 9.26% | 2026-09-30 |
| Goldman Sachs Group Inc | Institution (13F) | 7,748,378 | 2.07% | 2026-09-30 |
| Vanguard Capital Management LLC | Institution (13F) | 7,444,589 | 1.99% | 2026-09-30 |
| Two Sigma Investments, LP | Institution (13F) | 7,410,215 | 1.98% | 2026-09-30 |
| Acadian Asset Management. LLC | Institution (13F) | 7,239,297 | 1.93% | 2026-09-30 |
| MFN Partners Management, LP | Institution (13F) | 6,000,000 | 1.60% | 2026-09-30 |
| Gendell, Jeffrey L. | Institution (13F) | 4,189,291 | 1.12% | 2026-09-30 |
| Thomas Appio Chief Executive Officer, Director |
Insider | 2,315,374 | 0.62% | 2026-02-27 |
Share count 374,266,716 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-09-30 filed 2026-10-02 |
LEUNG SANDRA |
Award (A) | 5,789 | $5.83 | 102,859 |
| 2026-09-30 filed 2026-10-02 |
Paulson John |
Award (A) | 10,720 | $5.83 | 440,962 |
| 2026-09-30 filed 2026-10-02 |
WECHSLER AMY B |
Award (A) | 1,179 | $5.83 | 316,158 |
| 2026-08-19 filed 2026-08-20 |
Lenar Aimee J. |
Sale (S) | 36,827 | $7.03 | 334,853 |
| 2026-07-17 filed 2026-07-20 |
Lenar Aimee J. |
Tax withholding (F) | 5,260 | $4.83 | 371,680 |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BHC and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →